Hiroshi Kano
Papers
2
Total Citations
9
H-Index
2
About
Dr. Hiroshi Kano is a urologic oncologist whose research focuses on optimizing outcomes for prostate cancer patients undergoing robot-assisted radical prostatectomy (RARP). His work centers on two critical clinical challenges: understanding the prognostic significance of surgical margin status and managing biochemical recurrence (BCR) after surgery. In his most cited study (2021, 7 citations), Dr. Kano demonstrated that a positive surgical margin with a Gleason score of 6 does not significantly increase BCR risk compared to negative margins—a finding that challenges conventional assumptions and may spare some patients from unnecessary adjuvant therapy. His more recent investigation (2024) explores the role of salvage androgen deprivation therapy (ADT) for post-RARP recurrence, specifically examining intermittent versus continuous regimens in a Japanese cohort. This work addresses a critical gap in evidence for Asian populations. While still early in his career, Dr. Kano’s contributions are already shaping more nuanced, risk-adapted approaches to prostate cancer management, moving beyond binary margin-status thinking toward personalized treatment decisions based on tumor biology.
Research Focus
Key Achievements
Top Papers
- 1
- 2